DOAC Selection & Reversal

Choose apixaban/rivaroxaban/edoxaban/dabigatran by indication and CrCl; use idarucizumab, andexanet alfa, or 4-factor PCC for reversal.

Last generated Jan 2, 2026 UTC

DOAC Selection & Reversal

Master direct oral anticoagulant (DOAC) selection, dosing, and reversal strategies with free flashcards and spaced repetition practice. This lesson covers evidence-based DOAC selection for atrial fibrillation and venous thromboembolism, renal dose adjustments, drug interactions, and emergency reversal protocols—essential concepts for NAPLEX success and clinical practice.

Welcome to DOAC Selection & Reversal

Direct oral anticoagulants (DOACs) have revolutionized anticoagulation therapy, offering predictable pharmacokinetics without routine monitoring. However, clinical mastery requires understanding nuanced selection criteria, patient-specific dosing, and life-saving reversal strategies. This lesson equips you with high-yield knowledge for both exam success and safe clinical practice. 💊

Core Concepts

🎯 The DOAC Landscape: Four Key Players

Four DOACs dominate modern anticoagulation therapy:

<table> <tr> <th>DOAC</th> <th>Mechanism</th> <th>Renal Elimination</th> <th>Prodrug</th> <th>Key Feature</th> </tr> <tr> <td><strong>Dabigatran</strong></td> <td>Direct thrombin (Factor IIa) inhibitor</td> <td>80%</td> <td>✅ Yes</td> <td>Only DOAC with specific reversal agent</td> </tr> <tr> <td><strong>Rivaroxaban</strong></td> <td>Factor Xa inhibitor</td> <td>33%</td> <td>❌ No</td> <td>Once daily dosing (most indications)</td> </tr> <tr> <td><strong>Apixaban</strong></td> <td>Factor Xa inhibitor</td> <td>27%</td> <td>❌ No</td> <td>Lowest bleeding risk in trials</td> </tr> <tr> <td><strong>Edoxaban</strong></td> <td>Factor Xa inhibitor</td> <td>50%</td> <td>❌ No</td> <td>Requires initial parenteral anticoagulation for VTE</td> </tr> </table>

💡 Mnemonic - "DARE to stop clots": Dabigatran, Apixaban, Rivaroxaban, Edoxaban

🔍 DOAC Selection Criteria

Indication-Specific Considerations

Atrial Fibrillation (AFib) Stroke Prevention:

First-line recommendation: Any DOAC over warfarin (unless contraindicated)
Apixaban: Preferred in elderly patients (>75 years) or those with prior GI bleeding
Dabigatran 150 mg: Most effective stroke reduction (but higher GI bleeding risk than 110 mg)
Edoxaban: Contraindicated if CrCl >95 mL/min (reduced efficacy)

Venous Thromboembolism (VTE) Treatment:

Rivaroxaban & Apixaban: Can be used as monotherapy (no initial heparin bridge required)
Dabigatran & Edoxaban: Require 5-10 days parenteral anticoagulation before starting
Cancer-associated thrombosis: Apixaban or rivaroxaban now preferred over LMWH (based on ADAM-VTE, CARAVAGGIO trials)

Patient-Specific Factors

<table> <tr> <th>Factor</th> <th>Preferred DOAC</th> <th>Avoid</th> <th>Rationale</th> </tr> <tr> <td>CrCl 15-30 mL/min</td> <td>Apixaban 2.5 mg BID</td> <td>Dabigatran, edoxaban</td> <td>Least renal elimination</td> </tr> <tr> <td>CrCl <15 mL/min or dialysis</td> <td>Apixaban (off-label)</td> <td>All others</td> <td>No DOACs FDA-approved; warfarin preferred</td> </tr> <tr> <td>GI bleeding history</td> <td>Apixaban</td> <td>Dabigatran 150 mg, rivaroxaban</td> <td>Lower GI bleeding rates</td> </tr> <tr> <td>Dyspepsia/GERD</td> <td>Apixaban, rivaroxaban, edoxaban</td> <td>Dabigatran</td> <td>Dabigatran capsule contains tartaric acid</td> </tr> <tr> <td>Adherence concerns</td> <td>Rivaroxaban, edoxaban</td> <td>Twice-daily agents</td> <td>Once-daily dosing improves compliance</td> </tr> <tr> <td>Cost sensitivity</td> <td>Generic availability varies</td> <td>—</td> <td>Check formulary; all similar efficacy</td> </tr> </table>

⚠️ Critical Point: Edoxaban shows reduced efficacy when CrCl >95 mL/min due to increased renal clearance. Use alternative DOAC in these patients.

💊 Renal Dose Adjustments: The High-Yield Chart

<table> <tr> <th>DOAC</th> <th>Indication</th> <th>Standard Dose</th> <th>Renal Adjustment Criteria</th> <th>Adjusted Dose</th> </tr> <tr> <td rowspan="2"><strong>Dabigatran</strong></td> <td>AFib</td> <td>150 mg BID</td> <td>CrCl 15-30: reduce<br>CrCl <15: avoid</td> <td>75 mg BID</td> </tr> <tr> <td>VTE treatment</td> <td>150 mg BID</td> <td>CrCl <30: avoid</td> <td>Not recommended</td> </tr> <tr> <td rowspan="2"><strong>Rivaroxaban</strong></td> <td>AFib</td> <td>20 mg daily</td> <td>CrCl 15-50: reduce<br>CrCl <15: avoid</td> <td>15 mg daily</td> </tr> <tr> <td>VTE treatment</td> <td>15 mg BID × 21d → 20 mg daily</td> <td>CrCl <30: avoid</td> <td>—</td> </tr> <tr> <td rowspan="2"><strong>Apixaban</strong></td> <td>AFib</td> <td>5 mg BID</td> <td>2 of 3: SCr ≥1.5, age ≥80, wt ≤60 kg</td> <td>2.5 mg BID</td> </tr> <tr> <td>VTE treatment</td> <td>10 mg BID × 7d → 5 mg BID</td> <td>CrCl <25: use caution</td> <td>Standard dose</td> </tr> <tr> <td rowspan="2"><strong>Edoxaban</strong></td> <td>AFib</td> <td>60 mg daily</td> <td>CrCl 15-50 or wt ≤60 kg: reduce<br>CrCl <15 or >95: avoid</td> <td>30 mg daily</td> </tr> <tr> <td>VTE treatment</td> <td>60 mg daily</td> <td>CrCl 15-50 or wt ≤60 kg: reduce<br>CrCl <15: avoid</td> <td>30 mg daily</td> </tr> </table>

🧠 Memory Aid - "A-2-5 Rule": Apixaban dose reduces to 2.5 mg when you have 2 of 3 criteria (age ≥80, SCr ≥1.5, weight ≤60 kg)

💡 Pro Tip: Apixaban is the most "kidney-friendly" DOAC, suitable down to CrCl 15 mL/min with appropriate dosing.

⚡ Drug Interactions: The P-glycoprotein & CYP3A4 Connection

All DOACs are substrates of P-glycoprotein (P-gp), and the Factor Xa inhibitors also involve CYP3A4 metabolism.

Strong Dual Inhibitors (P-gp + CYP3A4) - AVOID or REDUCE DOSE

<pre> ❌ CONTRAINDICATED COMBINATIONS:

┌─────────────────────────────────────┐ │ Strong Dual Inhibitors │ ├─────────────────────────────────────┤ │ • Ketoconazole, itraconazole │ │ • Ritonavir, cobicistat │ │ • Clarithromycin │ │ │ │ Effect: ↑↑↑ DOAC levels │ │ Risk: Major bleeding │ └─────────────────────────────────────┘ ⚠️ │ ↓ DOAC levels TOO HIGH → bleeding </pre>

Clinical Action:

Rivaroxaban/Edoxaban: Avoid combination
Apixaban: Reduce dose by 50% (e.g., 5 mg → 2.5 mg BID)
Dabigatran: Avoid if CrCl <50; otherwise reduce to 75 mg BID

Strong Dual Inducers (P-gp + CYP3A4) - AVOID

<pre> ❌ CONTRAINDICATED COMBINATIONS:

┌─────────────────────────────────────┐ │ Strong Dual Inducers │ ├─────────────────────────────────────┤ │ • Rifampin │ │ • Carbamazepine │ │ • Phenytoin │ │ • St. John's Wort │ │ │ │ Effect: ↓↓↓ DOAC levels │ │ Risk: Loss of anticoagulation │ └─────────────────────────────────────┘ ⚠️ │ ↓ DOAC levels TOO LOW → clotting </pre>

Clinical Action: Avoid combination with all DOACs; use alternative anticoagulant (warfarin)

Important Single Pathway Interactions

<table> <tr> <th>Drug</th> <th>Mechanism</th> <th>Effect on DOACs</th> <th>Management</th> </tr> <tr> <td>Amiodarone</td> <td>P-gp inhibitor</td> <td>↑ Dabigatran, edoxaban significantly</td> <td>Reduce dabigatran to 75 mg BID if CrCl 30-50</td> </tr> <tr> <td>Verapamil</td> <td>P-gp inhibitor</td> <td>↑ Dabigatran levels</td> <td>Reduce dabigatran to 75 mg BID if CrCl 30-50</td> </tr> <tr> <td>Diltiazem</td> <td>Moderate CYP3A4/P-gp inhibitor</td> <td>Minor increase in DOAC levels</td> <td>Generally no adjustment needed; monitor</td> </tr> <tr> <td>Aspirin/NSAIDs</td> <td>Antiplatelet effect</td> <td>Additive bleeding risk</td> <td>Avoid unless specific indication (e.g., ACS)</td> </tr> </table>

🚨 DOAC Reversal Strategies: Life-Saving Knowledge

Specific Reversal Agents

<table> <tr> <th>Agent</th> <th>Reverses</th> <th>Mechanism</th> <th>Dose</th> <th>Onset</th> </tr> <tr> <td><strong>Idarucizumab</strong><br>(Praxbind®)</td> <td>Dabigatran ONLY</td> <td>Humanized monoclonal antibody fragment that binds dabigatran</td> <td>5 g IV (two 2.5 g doses)</td> <td>Minutes</td> </tr> <tr> <td><strong>Andexanet alfa</strong><br>(Andexxa®)</td> <td>Rivaroxaban<br>Apixaban<br>(Edoxaban)</td> <td>Recombinant Factor Xa decoy protein</td> <td>Low: 400 mg bolus → 4 mg/min × 2h<br>High: 800 mg bolus → 8 mg/min × 2h</td> <td>2-5 minutes</td> </tr> </table>

💡 Andexanet Dosing Decision Tree:

<pre> Dose Selection for Andexanet Alfa

 Is it rivaroxaban?
        │
  ┌─────┴─────┐
  │           │
YES          NO (apixaban/edoxaban)
  │           │
  ↓           ↓

10 mg? >5 mg? │ │ ┌───┴───┐ ┌───┴───┐ YES NO YES NO │ │ │ │ ↓ ↓ ↓ ↓ HIGH LOW HIGH LOW

HIGH = 800 mg bolus → 8 mg/min × 2h LOW = 400 mg bolus → 4 mg/min × 2h

Also use HIGH dose if:

Last dose >8 hours ago
Unknown timing </pre>

⚠️ Critical Limitations:

Idarucizumab: Only reverses dabigatran; no effect on Factor Xa inhibitors
Andexanet alfa: Very expensive ($$$); risk of thrombosis (10-15%); limited availability
Neither agent: Has outcome data showing mortality benefit (used for life-threatening bleeding or urgent surgery)

Non-Specific Hemostatic Agents

<table> <tr> <th>Agent</th> <th>Mechanism</th> <th>Dose</th> <th>Use Case</th> <th>Evidence</th> </tr> <tr> <td><strong>4-Factor PCC</strong><br>(Kcentra®)</td> <td>Replenishes vitamin K-dependent factors (II, VII, IX, X) + protein C/S</td> <td>25-50 units/kg IV</td> <td>Factor Xa inhibitor bleeding when andexanet unavailable</td> <td>Limited data; commonly used off-label</td> </tr> <tr> <td><strong>Activated PCC</strong><br>(FEIBA®)</td> <td>Activated factor VII bypasses Factor Xa</td> <td>50 units/kg IV (max 200 units/kg/day)</td> <td>Alternative if 4F-PCC unavailable</td> <td>Animal models only; higher thrombosis risk</td> </tr> <tr> <td><strong>Tranexamic acid</strong></td> <td>Antifibrinolytic (inhibits plasminogen activation)</td> <td>1 g IV over 10 min</td> <td>Adjunctive therapy; major bleeding</td> <td>Reduces blood loss in trauma/surgery</td> </tr> <tr> <td><strong>Recombinant Factor VIIa</strong></td> <td>Activates coagulation pathway</td> <td>90 mcg/kg IV</td> <td>Last resort; refractory bleeding</td> <td>Very limited data; high thrombosis risk</td> </tr> </table>

🧠 Reversal Strategy Algorithm:

<pre> DOAC-Associated Major Bleeding │ ↓ ┌─────────────────────┐ │ Identify DOAC │ │ Time since last dose│ │ Renal function │ └──────────┬──────────┘ │ ┌───────┴────────┐ │ │ Dabigatran Factor Xa inhibitor │ │ ↓ ↓ IDARUCIZUMAB ANDEXANET ALFA 5 g IV stat (if available) │ │ │ ├─→ If unavailable: │ │ 4F-PCC 25-50 u/kg │ │ └────────┬───────┘ │ ↓ ┌───────────────────────┐ │ SUPPORTIVE MEASURES: │ ├───────────────────────┤ │ • Hold DOAC │ │ • IV fluids │ │ • Transfuse PRBCs │ │ • Tranexamic acid │ │ • Local measures │ │ • Hemodialysis (dabi) │ └───────────────────────┘ </pre>

💡 Special Note on Dabigatran: Because it's 80% renally eliminated and has small molecular weight, hemodialysis can remove ~60% in 2-4 hours. Consider in addition to idarucizumab for severe bleeding.

Minor Bleeding Management

For minor bleeding (epistaxis, microscopic hematuria, small ecchymoses):

Delay or skip next dose (DOACs have short half-lives: 5-17 hours)
Apply local measures (pressure, ice, nasal packing)
Supportive care (fluids, monitor CBC)
Restart DOAC once bleeding controlled (usually 24-48 hours)

⚠️ Common Mistake: Using reversal agents for minor bleeding. These are expensive, prothrombotic, and unnecessary when holding the DOAC alone suffices.

🔄 Periprocedural Management

DOAC Interruption Guidelines:

<table> <tr> <th>Bleeding Risk</th> <th>CrCl ≥50 mL/min</th> <th>CrCl 30-50 mL/min</th> <th>CrCl 15-30 mL/min</th> </tr> <tr> <td><strong>Low risk</strong><br>(dental, cataract, endoscopy without biopsy)</td> <td>Hold 24h before<br>(skip 1-2 doses)</td> <td>Hold 36h before<br>(skip 2-3 doses)</td> <td>Hold 48h before<br>(skip 3-4 doses)</td> </tr> <tr> <td><strong>High risk</strong><br>(major surgery, neuraxial anesthesia, organ biopsy)</td> <td>Hold 48h before<br>(skip 2-4 doses)</td> <td>Hold 72h before<br>(skip 4-6 doses)</td> <td>Hold 96h before<br>(skip 6-8 doses)</td> </tr> </table>

Resumption After Procedure:

Low bleeding risk: Resume 6-8 hours post-procedure (once hemostasis established)
High bleeding risk: Resume 48-72 hours post-procedure
Major surgery with ongoing bleeding risk: Consider prophylactic dose initially, then full dose at 48-72 hours

💡 Pro Tip: No "bridging" anticoagulation needed for DOACs (unlike warfarin). Their rapid onset/offset makes bridging unnecessary and potentially harmful.

Examples

Example 1: DOAC Selection in Complex Patient

Case: 78-year-old female with AFib (CHA₂DS₂-VASc = 5), CrCl 35 mL/min, weight 58 kg, history of dyspepsia on PPIs. She needs stroke prevention.

Analysis:

<table> <tr> <th>Consideration</th> <th>Assessment</th> <th>Impact on Selection</th> </tr> <tr> <td>Renal function</td> <td>CrCl 35 mL/min (moderate impairment)</td> <td>• Dabigatran 75 mg BID<br>• Rivaroxaban 15 mg daily<br>• Apixaban 2.5 mg BID (if meets criteria)<br>• Edoxaban 30 mg daily</td> </tr> <tr> <td>Apixaban criteria</td> <td>Age 78 (≥80? NO)<br>Weight 58 kg (≤60? YES)<br>SCr unknown, assume <1.5</td> <td>Only 1 of 3 criteria → use 5 mg BID (NOT 2.5 mg)</td> </tr> <tr> <td>Dyspepsia history</td> <td>Sensitive to GI irritation</td> <td>Avoid dabigatran (tartaric acid in capsule)</td> </tr> </table>

Best Options:

Apixaban 5 mg BID (only 1 dose-reduction criterion met; GI-friendly)
Rivaroxaban 15 mg daily (once-daily dosing; take with food)
Edoxaban 30 mg daily (appropriate renal dose; once daily)

Avoid: Dabigatran (dyspepsia concern + requires BID dosing)

Answer: Apixaban 5 mg BID is optimal given GI tolerance, appropriate dosing, and favorable bleeding profile in elderly.

Example 2: Drug Interaction Management

Case: 65-year-old male on rivaroxaban 20 mg daily for AFib develops systemic fungal infection requiring itraconazole 200 mg BID.

Problem: Itraconazole is a strong dual inhibitor (P-gp + CYP3A4) → will significantly increase rivaroxaban levels → major bleeding risk

Options:

<table> <tr> <th>Strategy</th> <th>Pros</th> <th>Cons</th> <th>Recommendation</th> </tr> <tr> <td>Reduce rivaroxaban dose</td> <td>Maintains DOAC therapy</td> <td>No evidence-based reduced dose for this interaction</td> <td>❌ Not recommended</td> </tr> <tr> <td>Switch to apixaban</td> <td>Can reduce apixaban by 50% with documentation</td> <td>Still significant interaction risk</td> <td>⚠️ Possible but suboptimal</td> </tr> <tr> <td>Switch to warfarin</td> <td>No P-gp/CYP3A4 interaction</td> <td>Requires monitoring; interaction with azoles (CYP2C9)</td> <td>✅ Best option with close INR monitoring</td> </tr> <tr> <td>Use alternative antifungal</td> <td>Avoids anticoagulant change</td> <td>May not be therapeutically equivalent</td> <td>✅ Consider if clinically appropriate</td> </tr> </table>

Best Approach:

Consult ID team - can fluconazole (moderate inhibitor) or alternative be used?
If itraconazole mandatory: Switch to warfarin, target INR 2-3, monitor weekly initially (azoles increase warfarin effect via CYP2C9 inhibition)
Once antifungal course complete: Can transition back to DOAC

Example 3: Emergency Reversal Scenario

Case: 72-year-old male on apixaban 5 mg BID (last dose 4 hours ago) presents with acute subdural hematoma after fall. Neurosurgery needed within 2 hours. BP 185/105, declining GCS.

Reversal Plan:

<pre> TIME-CRITICAL REVERSAL PROTOCOL

⏰ T = 0 minutes (presentation) ├─→ Neurosurgery consultation ├─→ CBC, PT/PTT, renal function, type & cross └─→ CT head (confirms subdural)

⏰ T = 15 minutes ├─→ Andexanet alfa HIGH DOSE: │ • 800 mg IV bolus over 15 min │ • Then 8 mg/min × 120 min infusion ├─→ If andexanet unavailable: │ • 4F-PCC 50 units/kg IV │ • Tranexamic acid 1 g IV └─→ Blood pressure control: nicardipine gtt (Goal SBP <140 to reduce hematoma expansion)

⏰ T = 30 minutes └─→ Repeat coagulation assessment (anti-Xa assay if available)

⏰ T = 90-120 minutes └─→ Proceed to OR when hemostasis optimized

POST-OPERATIVE: • Hold apixaban minimum 48-72h • Monitor for hematoma re-expansion • Consider VTE prophylaxis (mechanical → LMWH) • Restart anticoagulation when bleeding risk acceptable (typically 7-14 days post-op, neurosurgery approval) </pre>

Key Teaching Points:

Life-threatening bleeding = indication for reversal agent
Time since last dose matters less in emergent scenarios
Supportive care (BP control, transfusion) equally important
Consider thrombosis risk after andexanet (10-15% rate)
Plan for restarting anticoagulation (stroke risk remains!)

Example 4: Periprocedural Management

Case: 68-year-old on dabigatran 150 mg BID (CrCl 65 mL/min) scheduled for colonoscopy with planned polypectomy in 5 days.

Risk Assessment:

Procedure bleeding risk: HIGH (polypectomy involves tissue removal)
Thrombotic risk: Moderate (AFib with CHA₂DS₂-VASc = 3)
Renal function: Normal

Management Plan:

<table> <tr> <th>Timeline</th> <th>Action</th> <th>Rationale</th> </tr> <tr> <td>Day -2 (3 days before)</td> <td>Last dose of dabigatran: morning of Day -2</td> <td>48h interruption for high bleeding risk with normal renal function</td> </tr> <tr> <td>Day -1</td> <td>No dabigatran; ensure coagulation normalized</td> <td>Half-life 12-17h; 48h = 3-4 half-lives</td> </tr> <tr> <td>Day 0 (procedure day)</td> <td>Perform colonoscopy; no bridging anticoagulation</td> <td>DOACs don't require bridging (unlike warfarin)</td> </tr> <tr> <td>Day 0 (evening)</td> <td>If no bleeding: restart dabigatran 150 mg</td> <td>Low-risk polypectomy, hemostasis confirmed</td> </tr> <tr> <td>Day +1</td> <td>Resume regular BID dosing</td> <td>Full anticoagulation restored</td> </tr> </table>

Alternative Scenario: If large polyp removed or bleeding observed:

Delay dabigatran restart 24-48 hours
Consider prophylactic enoxaparin 40 mg SC daily if high thrombotic risk
Resume dabigatran when GI team confirms adequate hemostasis

💡 Pro Tip: Always coordinate timing with proceduralist. Some prefer longer interruption for complex cases; respect their bleeding risk assessment.

Common Mistakes

❌ Mistake #1: Inappropriate Dose Reduction

Error: Reducing apixaban to 2.5 mg BID in elderly patient with AFib based on age alone.

Why It's Wrong: Apixaban dose reduction requires 2 of 3 criteria (age ≥80, SCr ≥1.5, weight ≤60 kg). Age 75 alone doesn't qualify.

Consequence: Underdosing → inadequate stroke prevention → preventable stroke

Correct Approach: Use 5 mg BID unless patient meets 2 of 3 dose-reduction criteria. Age must be ≥80 (not just "elderly").

❌ Mistake #2: Using Edoxaban with High CrCl

Error: Prescribing edoxaban 60 mg daily for AFib patient with CrCl 110 mL/min.

Why It's Wrong: Edoxaban shows reduced efficacy when CrCl >95 mL/min due to excessive renal clearance (ENGAGE AF-TIMI 48 trial subgroup analysis).

Consequence: Subtherapeutic anticoagulation → increased stroke risk

Correct Approach: Select alternative DOAC (apixaban, rivaroxaban, or dabigatran) for patients with CrCl >95 mL/min.

❌ Mistake #3: Bridging DOACs Like Warfarin

Error: Prescribing enoxaparin "bridge" when interrupting rivaroxaban for surgery.

Why It's Wrong: DOACs have rapid onset (2-4 hours) and offset (half-life 5-17 hours). Bridging is:

Unnecessary (no therapeutic gap)
Dangerous (increases bleeding without reducing thrombosis)
Based on warfarin principles (which don't apply to DOACs)

Consequence: Perioperative bleeding without benefit

Correct Approach: Simply hold DOAC 24-96 hours before procedure (based on renal function and bleeding risk), then resume postoperatively. No bridge needed.

❌ Mistake #4: Reversal Agent Misuse

Error: Administering andexanet alfa for apixaban-associated minor epistaxis.

Why It's Wrong:

Minor bleeding doesn't require reversal (holding DOAC suffices)
Andexanet carries 10-15% thrombosis risk
Cost: ~$50,000 per dose
Reserve for life-threatening bleeding or emergent surgery

Consequence: Unnecessary thrombotic risk and healthcare expenditure

Correct Approach:

Minor bleeding: Hold DOAC, local measures, supportive care
Moderate bleeding: Hold DOAC, consider non-specific agents (TXA)
Life-threatening bleeding: Specific reversal agent (idarucizumab or andexanet)

❌ Mistake #5: Giving Rivaroxaban Without Food

Error: Instructing patient to take rivaroxaban 20 mg "on empty stomach for better absorption."

Why It's Wrong: Rivaroxaban 15 mg and 20 mg tablets require food for adequate absorption (10 mg dose does not). Without food, bioavailability decreases ~30%.

Consequence: Subtherapeutic anticoagulation → treatment failure

Correct Approach:

Rivaroxaban 15 mg or 20 mg: Take with food (specifically the largest meal of the day)
Rivaroxaban 10 mg: Can take without regard to meals
All other DOACs: Can take without regard to meals

Key Takeaways

<div style="border: 2px solid #4fd1c5; border-radius: 8px; padding: 16px; margin: 16px 0; background: rgba(79, 209, 197, 0.1);"> <h4>📋 Quick Reference Card: DOAC Mastery</h4>

<table> <tr> <th>Category</th> <th>Critical Points</th> </tr> <tr> <td><strong>🎯 DOAC Selection</strong></td> <td>• Apixaban: lowest bleeding risk, best for renal impairment<br>• Rivaroxaban: once daily convenience<br>• Dabigatran: only DOAC with specific reversal<br>• Edoxaban: avoid if CrCl >95 mL/min</td> </tr> <tr> <td><strong>💊 Dosing Pearls</strong></td> <td>• Apixaban: 2 of 3 criteria for dose reduction (age ≥80, SCr ≥1.5, wt ≤60)<br>• Rivaroxaban ≥15 mg: must take with food<br>• Dabigatran: 75 mg BID if CrCl 15-30 for AFib<br>• All DOACs: adjust for renal function</td> </tr> <tr> <td><strong>⚡ Drug Interactions</strong></td> <td>• Avoid strong dual P-gp/CYP3A4 inhibitors (ketoconazole, ritonavir)<br>• Avoid strong dual inducers (rifampin, carbamazepine)<br>• Reduce apixaban 50% with strong dual inhibitors<br>• All DOACs: caution with antiplatelet agents</td> </tr> <tr> <td><strong>🚨 Reversal</strong></td> <td>• Idarucizumab 5 g IV for dabigatran (specific)<br>• Andexanet alfa for Factor Xa inhibitors (dose based on drug/amount)<br>• 4F-PCC 25-50 u/kg if andexanet unavailable<br>• Hemodialysis removes dabigatran (80% renal elimination)</td> </tr> <tr> <td><strong>🔄 Periprocedural</strong></td> <td>• NO bridging needed (unlike warfarin)<br>• Hold 24-96h before surgery (based on CrCl and bleeding risk)<br>• Low risk: resume 6-8h post-op<br>• High risk: resume 48-72h post-op</td> </tr> <tr> <td><strong>⚠️ Common Errors</strong></td> <td>• Don't underdose apixaban based on age <80 alone<br>• Don't use edoxaban if CrCl >95<br>• Don't bridge DOACs perioperatively<br>• Don't reverse for minor bleeding<br>• Don't forget food with rivaroxaban ≥15 mg</td> </tr> </table>

🧠 Final Mnemonic - "RAPID" DOAC Management:

Renal function guides dosing
Avoid strong dual inhibitors/inducers
Procedure timing: stop 24-96h before
Idarucizumab for dabigatran, andexanet for Xa inhibitors
Don't bridge (no LMWH needed perioperatively)

</div>

📚 Further Study

CHEST Guidelines on Antithrombotic Therapy: Comprehensive evidence-based recommendations for DOAC use across indications
https://www.chestnet.org/guidelines-and-resources
American College of Cardiology DOAC Practical Guide: Includes interactive clinical scenarios and periprocedural algorithms
https://www.acc.org/latest-in-cardiology/articles/2020/07/06/09/42/practical-approach-to-doacs
Thrombosis Canada - DOAC Reversal Guidelines: Detailed protocols for emergency reversal including andexanet dosing calculator
https://thrombosiscanada.ca/clinicalguides/

🎓 You've now mastered DOAC selection, dosing, interactions, and reversal strategies—high-yield knowledge that will serve you on the NAPLEX and in clinical practice. Remember: individualize therapy based on renal function, comorbidities, and drug interactions, and reserve reversal agents for truly life-threatening scenarios.

📝

Ready to practice?

This lesson has 15 questions to help you learn